Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Acute conjunctivitis: truth and misconceptions
Current Medical Research and Opinion, 07/01/09
O'Brien TP et al. - Considerable light has been shed on acute microbial conjunctivitis and especially those cases caused by adenovirus. Many of the myths that have perpetuated for years have been debunked by emerging evidence. The advent and the implementation of better diagnostic tools and anti-viral medications will help clinicians to improve their diagnostic accuracy, improve management and treatment decisions, and ultimately benefit patients while saving overall healthcare costs.
Related Articles
Successful treatment of ligneous conjunctivitis with topical cyclosporine and heparin
Journal of American Association for Pediatric Ophthalmology and Strabismus, 11/03/09
Relevance Score: 88%
Evidence-based treatment of acute infective conjunctivitis: Breaking the cycle of antibiotic prescribing
Canadian Family Physician, 11/13/09
Relevance Score: 87%
Effect of oral azithromycin in the treatment of chlamydial conjunctivitis
Eye, 11/09/09
Relevance Score: 85%
Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: A phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children
Clinical Therapeutics, 10/29/09
Relevance Score: 85%
Relationship between myopia and allergen-specific serum IgE levels in patients with allergic conjunctivitis
Clinical and Experimental Ophthalmology, 10/09/09
Relevance Score: 84%
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Spiperone enhances intracellular calcium level and inhibits the Wnt signaling pathway
BMC Pharmacology, 12/02/09
The Intersection of Safety and Adherence: New Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus
Pharmacotherapy, 12/02/09
Clinical Studies of Liraglutide, a Novel, Once-Daily Human Glucagon-Like Peptide-1 Analog for Improved Management of Type 2 Diabetes Mellitus
Pharmacotherapy, 12/02/09
Sponsor
Article Search
Sponsor


See Latest Articles


